Cocrystal pharma reports q1 2020 financial results and provides updates on antiviral programs

Cocrystal pharma reports first quarter 2020 financial results and provides updates on antiviral programs.q1 revenue $461,000 versus $5.078 million.company has sufficient capital to advance pipeline and fund operations through 2021.cocrystal pharma - advancing coronavirus program by leveraging rights to preclinical leads from its license agreements with ksurf.intends to identify additional covid-19 inhibitors from ksurf.
COCP Ratings Summary
COCP Quant Ranking